MG
OBIO icon

Michael Gelband’s Orchestra BioMed OBIO Stock Holding History

Michael Gelband’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-95,635
Closed -$397K – 1938
2025
Q4 		$397K Buy
+95,635
New +$386K ﹤0.01% 1235
2021
Q1 		– Sell
-29,800
Closed -$382K – 2457
2020
Q4 		$382K Buy
+29,800
New +$340K ﹤0.01% 1409

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Michael Gelband's OBIO Position: Q1 2026 in Review

Michael Gelband sold out of Orchestra BioMed (OBIO) in Q1 2026, closing a stake of 95,635 shares — an estimated $397K sold.

Michael Gelband first reported a position in OBIO in Q4 2020 and held it in 2 quarters. The position peaked at $397K in Q4 2025. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Michael Gelband reported no remaining Orchestra BioMed position as of Q1 2026 after selling out during the quarter.
  • Michael Gelband sold 95,635 Orchestra BioMed shares in Q1 2026, an estimated $397K.
  • Michael Gelband first reported a position in Orchestra BioMed in Q4 2020 and held it in 2 quarters.
  • Michael Gelband's Orchestra BioMed position peaked at $397K in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.